[A clinical study of hehuantang in treating coronary heart disease].
Fifty-nine cases with angina pectoris (AP) in coronary heart disease were divided randomly into two groups, 37 cases of Hehuantang group (HT) treated with Hehuantang, 22 cases of patient treated with nifedipine tablet was taken as control group (CG).


RESULTS
(1) the marked effective and total effective rate in allevating AP was 75.68% and 91.89% in HT respectively; (2) activities of serum SOD and whole blood GSH-Px in HT significantly elevated than that pretreatmentally (P < 0.01); (3) comparing with CG, SOD activity and GSH-Px/LPO ratio increased (P < 0.01 and P < 0.05), whereas plasma LPO content lowered (P < 0.05). It suggested that HT having effects of relieve AP and enhance antioxidative activity and attenuate lipid peroxide reaction. The mechanism might be correlated to inhibit the calcium overload and reduce LPO production in cardiac cell as well as improve blood supply to myocardial ischemia.
Cai
P Y
PY
Shanghai Integrated Traditional and Western Medicine Hospital.
Xu
B T
BT
Shen
B Y
BY
D000368:Aged; D000369:Aged, 80 and over; D000787:Angina Pectoris / Q000097:blood / Q000188:drug therapy*; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use*; D005979:Glutathione Peroxidase / Q000097:blood; D006801:Humans; D008054:Lipid Peroxides / Q000097:blood; D008297:Male; D008875:Middle Aged; D009543:Nifedipine / Q000627:therapeutic use; D013482:Superoxide Dismutase / Q000097:blood; D014665:Vasodilator Agents / Q000627:therapeutic use
D004365:Drugs, Chinese Herbal; D008054:Lipid Peroxides; D014665:Vasodilator Agents; D005979:Glutathione Peroxidase; D013482:Superoxide Dismutase; D009543:Nifedipine